CTT Pharmaceutical Holdings (CTT Pharmaceutical Holdings) Operating Income : $-1.19 Mil (TTM As of Jun. 2018)

View and export this data going back to . Start your Free Trial

What is CTT Pharmaceutical Holdings Operating Income?

CTT Pharmaceutical Holdings's Operating Income for the three months ended in Jun. 2018 was $-1.09 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2018 was $-1.19 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. CTT Pharmaceutical Holdings's Operating Income for the three months ended in Jun. 2018 was $-1.09 Mil. CTT Pharmaceutical Holdings's Revenue for the three months ended in Jun. 2018 was $0.00 Mil. Therefore, CTT Pharmaceutical Holdings's Operating Margin % for the quarter that ended in Jun. 2018 was %.

CTT Pharmaceutical Holdings's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. CTT Pharmaceutical Holdings's annualized ROC % for the quarter that ended in Jun. 2018 was -17,440.00%. CTT Pharmaceutical Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2018 was %.

CTT Pharmaceutical Holdings Operating Income Historical Data

The historical data trend for CTT Pharmaceutical Holdings's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CTT Pharmaceutical Holdings Operating Income Chart

CTT Pharmaceutical Holdings Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Operating Income

Get a 7-Day Free Trial

-0.76

-1.10

-0.02

-0.67

-1.45

CTT Pharmaceutical Holdings Quarterly Data
	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Mar17	Jun17	Mar18	Jun18
Operating Income	Get a 7-Day Free Trial															-0.14	-0.03	-0.14	-0.10	-1.09

CTT Pharmaceutical Holdings Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.19 Mil.

CTT Pharmaceutical Holdings (OTCPK:CTTH) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

CTT Pharmaceutical Holdings's annualized ROC % for the quarter that ended in Jun. 2018 is calculated as:

	ROC % (Q: Jun. 2018 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2018 )	+	Invested Capital (Q: Jun. 2018 ))	/ count )
=	-4.36 * ( 1 - 0% )	/	( (0.025	+	0.025)	/ 2 )
=	-4.36	/	0.025
=	-17,440.00 %

where

	Invested Capital		(Q: Mar. 2018 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.156	-	0.258	-	( 0.106	-	max(0, 0.283	-	0.156	+	0.106	))
=	0.025

	Invested Capital		(Q: Jun. 2018 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.996	-	0.268	-	( 0.996	-	max(0, 0.293	-	0.996	+	0.996	))
=	0.025

Note: The Operating Income data used here is four times the quarterly (Jun. 2018) data.

2. Joel Greenblatt's definition of Return on Capital:

CTT Pharmaceutical Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2018 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2018 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2018		Q: Jun. 2018
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-4.36	/	( ( (0 + max(-0.283, 0))	+	(0 + max(-0.293, 0)) )	/	2 )
=	-4.36	/	( ( 0	+	0 )	/	2 )
=	-4.36	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Mar. 2018 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0.258	+	0.025	+	-5.5511151231258E-17)
=	-0.283

	Working Capital		(Q: Jun. 2018 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0.268	+	0.025	+	-5.5511151231258E-17)
=	-0.293

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2018) EBIT data.

3. Operating Income is also linked to Operating Margin %:

CTT Pharmaceutical Holdings's Operating Margin % for the quarter that ended in Jun. 2018 is calculated as:

Operating Margin %	=	Operating Income (Q: Jun. 2018 )	/	Revenue (Q: Jun. 2018 )
	=	-1.09	/	0
	=	%

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

CTT Pharmaceutical Holdings Operating Income Related Terms

Thank you for viewing the detailed overview of CTT Pharmaceutical Holdings's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

CTT Pharmaceutical Holdings (CTT Pharmaceutical Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CTT Pharmaceutical Holdings Inc (OTCPK:CTTH) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

1100 – 1111 Melville Street, Vancouver, BC, CAN, V6E 3V6

Website

https://www.cttpharmaceuticals.com

CTT Pharmaceutical Holdings Inc is a development stage company specializing in drug delivery systems technology within the pharmaceutical industry. It focuses on fast-dissolving drug delivery systems through the development of oral delivery thin wafers. The thin wafers are infused with both natural and synthetic cannabis extracts to deliver treatment as an alternative to smoking and ingestion. Its products include Medwafe, Cannawafe, Vetwafe, and others.

Executives